Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials

1995 • 2,804 citations

Epidermal growth factor-related peptides and their receptors in human malignancies

1995 • 2,689 citations

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

1975 • 2,224 citations

Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy

2000 • 2,156 citations

Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens

2000 • 1,359 citations

ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial

2002 • 764 citations

Reliability and validity of the functional assessment of cancer therapy—lung (FACT-L) quality of life instrument

1995 • 713 citations

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1992 • 619 citations

Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung.

1993 • 482 citations

Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression.

1997 • 404 citations

What is a clinically meaningful change on the Functional Assessment of Cancer Therapy–Lung (FACT-L) Questionnaire?Results from Eastern Cooperative Oncology Group (ECOG) Study 5592

2002 • 373 citations

Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology.

1997 • 350 citations

Protein Kinase InhibitorsThe Tyrosine-Specific Protein Kinases

1998 • 197 citations

Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas

1998 • 183 citations

Current Standards of Care in Small-Cell and Non-Small-Cell Lung Cancer

2001 • 154 citations

A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer

1996 • 152 citations

Evidence for a role of EGF receptor in the progression of human lung carcinoma.

1993 • 131 citations

Second-Line Chemotherapy in Relapsing or Refractory Non–Small-Cell Lung Cancer: A Review

2000 • 124 citations

Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: A review of two phase III trials

2001 • 70 citations

Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 (IressaTM), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR)

2000 • 67 citations

Management strategies for recurrent non-small cell lung cancer.

1997 • 66 citations

Response to chemotherapy, quality of life benefits and survival in advanced non-small cell lung cancer: review of literature results

2001 • 64 citations

The Pursuit of Optimal Outcomes in Cancer Therapy in a New Age of Rationally Designed Target-Based Anticancer Agents

2000 • 62 citations

Staging of non-small cell lung cancer: consensus, controversies and challenges

2001 • 48 citations

Gemcitabine and carboplatin for patients with advanced non-small cell lung cancer

2001 • 7 citations